DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies [Yahoo! Finance]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Yahoo! Finance
Cologne, Germany, January 7, 2026 – DISCO Pharmaceuticals (“DISCO”), today announced an exclusive license agreement with Amgen to advance novel therapeutic candidates addressing a target that was mapped on the surface of a cancer cell by DISCO's proprietary platform. Under the terms of the agreement, DISCO will be eligible to receive up to $618 million total potential deal value plus royalties. Amgen will receive exclusive global rights to develop and commercialize the resulting programs directed against the target. “This agreement demonstrates the potential of our surfaceome mapping platform technology to uncover cancer cell surface targets with meaningful clinical potential,” commented Mark Manfredi, Ph.D., CEO of DISCO Pharmaceuticals . “The collaboration with Amgen enables us to potentially translate these biological insights into innovative therapies and accelerate our shared goal of delivering better outcomes for patients.” “Joining forces with a recognized global leader
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- Amgen (NASDAQ:AMGN) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.MarketBeat
- Should Amgen's (AMGN) Exclusive DISCO Oncology Deal Require Action From Investors? [Yahoo! Finance]Yahoo! Finance
- BioLab Holdings Announces Significant Team Growth Across Key Departments [Yahoo! Finance]Yahoo! Finance
- Amgen (NASDAQ:AMGN) had its price target raised by analysts at Truist Financial Corporation from $318.00 to $319.00. They now have a "hold" rating on the stock.MarketBeat
- ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies [Yahoo! Finance]Yahoo! Finance
AMGN
Earnings
- 11/4/25 - Beat
AMGN
Sec Filings
- 11/21/25 - Form 4
- 11/20/25 - Form 144
- 11/13/25 - Form 4
- AMGN's page on the SEC website